Testing for KRAS mutation in only 1 of the primary lesions in SP-CRC might yield an incomplete profile on KRAS and NRAS mutation status and can misguide the clinical decision with regard to anti-EGFR treatment. The gene discussed is NRAS; the disease is colorectal carcinoma.